Moby summary of Acurx Pharmaceuticals, Inc.'s Q1 2026 earnings call
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
High-signal headlines only — macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Moby summary of Acurx Pharmaceuticals, Inc.'s Q1 2026 earnings call
Moby summary of Zebra Technologies Corporation's Q1 2026 earnings call
Moby summary of Lithium Argentina AG's Q1 2026 earnings call
Despite a dip in operating profit, Bytes Technology Group PLC (STU:9NY) showcases resilience with strong cash conversion and strategic partnerships driving future growth.
Moby summary of Vishay Precision Group, Inc.'s Q1 2026 earnings call
Moby summary of Under Armour, Inc.'s Q4 2026 earnings call
Anthropic is diving further into the legal software market.
Further, over half of that production trades on Connect our whole loan marketplace. This capital market, not the originating technologies are moat in this business and our primary revenue driver for loans in our ecosystem. Last year, we began to bring our digital assets over to DeFi for financing, introduced the problems remain to all real-world assets on blockchain.
Moby summary of TON Strategy Co.'s Q1 2026 earnings call
Moby summary of T1 Energy Inc's Q1 2026 earnings call
Analysts initiated covered Tuesday of IPO stock Kailera Therapeutics, a potential competitor to Lilly and Novo in obesity treatment.
Before we begin today's call, I would like to remind you that we will be referring to certain non-IFRS measures making certain statements regarding First Majestic Silver and its operations that constitute forward looking statements in accordance with applicable Canadian and U. S. Securities laws. Much of the improvements that the business has experienced over the last few years has been a result of Steven efforts.
With me today on the call are Caspar Coppetti, Founder and Co-CEO; Martin Hoffmann, outgoing CEO and CFO; and Frank Sluis, our new CFO as of May 1; David Allemann, Founder and Co-CEO, will also join us for the Q&A session. With that, I'm very happy to turn the call over to Caspar.
Forrest Li: Hello, everyone, and thank you for joining today's call. As we have shared before, 2026 is a year where we are leaning into growth investments to deepen our competitive moat while maintaining financial discipline. Starting with Shopee, Shopee delivered another record second quarter, achieving new highs in GMV, gross order volumes and revenue.
US equity indexes fell in Tuesday's midday trading as a hotter-than-expected inflation print for Apr
Nebius has had one of the more remarkable runs of any stock in the AI infrastructure space. Up more than 110% year to date and roughly 600% over the past year, the company is heading into its Q1 2026 earnings report on May 13 with enormous expectations built in. Bank of America just made those ...
The Treasury is set to auction $42 billion worth of bonds that expire in 10 years this afternoon. The auction comes after the latest inflation report revealed that the central bank remains far from its 2% target. Expectations of stubborn prices make investors demand higher yields to make up for the loss in a bonds’ purchasing power.
Alphabet's Google is in talks with Elon Musk's SpaceX for a rocket launch deal as the search giant looks to put orbital data centers in space, the Wall Street Journal reported on Tuesday, citing people familiar with the discussions. Google is also in discussions about a potential deal with other rocket-launch companies, the report said. SpaceX and Google did not immediately respond to Reuters' requests for comments.
FIG heads into Q1 earnings results with strong AI product traction, rising enterprise adoption and expanding international revenue growth.
A deal between the two tech titans would give a boost to SpaceX’s business ahead of a historic public listing.
There's a certain kind of analyst who doesn't talk much when he's wrong and doesn't celebrate long when he's right. Stephen "Sarge" Guilfoyle is that kind of analyst. Sarge is a former NYSE floor trader with more than 30 years of experience and the founder and president of Sarge986 LLC. On Friday, ...
(Bloomberg) -- US President Donald Trump is showing signs of frustration at a lack of progress in negotiations to end the 10-week war with Iran, as the Strait of Hormuz remains all but closed to vital energy supplies and oil prices continue to rise.Most Read from BloombergInside a Year of Chaos and Conflict at Kevin Hart’s Media CompanyIran Makes New Offer on Uranium in Response to US, WSJ SaysAmbani’s Cola War With Coke, Pepsi Spurs Fridge Bonanza in IndiaNvidia’s CEO to Miss China Trip After Y
Over the past six months, Charles Schwab’s shares (currently trading at $89.40) have posted a disappointing 6.5% loss, well below the S&P 500’s 7.7% gain. This might have investors contemplating their next move.
The April jobs report showed some areas of weakness in the labor market, while consumer prices came in slightly higher than expected.
A big part of the challenge is producing and launching scores of the devices without breaking the bank.
NVIDIA (NASDAQ:NVDA) stock just earned a fresh endorsement from Wells Fargo, which raised its price target to $315 from $265 and reiterated its Overweight rating on NVIDIA. The price target raise lands just eight days before NVIDIA’s quarterly report on May 20, with the firm arguing the stock still trades at less than 20 times ... Wells Fargo Hikes NVIDIA Price Target to $315 Ahead of Earnings: Is the AI King Still Cheap at 20x P/E?
Isomorphic Labs, an artificial intelligence-driven drug discovery company, said on Wednesday it has raised $2.1 billion in its latest funding round led by existing investor Thrive Capital. The funding round, completed at an undisclosed valuation, also included other existing investors, Google Ventures and Alphabet, along with new backers MGX, Temasek and CapitalG. "This capital injection allows us to build out our drug design engine at scale, driving us forward in our mission to solve all diseases," said founder and CEO Demis Hassabis.
Novanta (NASDAQ:NOVT) reported stronger-than-expected first-quarter 2026 results, with management citing broad-based bookings growth, accelerating demand in automation and medical markets, and rising exposure to artificial intelligence-related infrastructure applications. Chair and Chief Executive